PMID- 24647150
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20240314
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 3
DP  - 2014
TI  - Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 
      years after disease onset; associations with disease activity, duration and organ 
      damage.
PG  - e92171
LID - 10.1371/journal.pone.0092171 [doi]
LID - e92171
AB  - OBJECTIVE: To compare cytokine profiles in patients with juvenile dermatomyositis 
      (JDM) after medium to long-term follow-up with matched controls, and to examine 
      associations between cytokine levels and disease activity, disease duration and 
      organ damage. METHODS: Fifty-four JDM patients were examined median 16.8 years 
      (2-38) after disease onset (follow-up) and compared with 54 sex- and age-matched 
      controls. Cytokine concentrations in serum were quantified by Luminex technology. 
      In patients, disease activity score (DAS), myositis damage index (MDI) and other 
      disease parameters were collected by chart review (early parameters) and clinical 
      examination (follow-up). RESULTS: Serum levels of eotaxin, monocyte 
      chemoattractant protein-1 (MCP-1) and interferon-inducible protein 10 (IP-10) 
      were elevated in JDM patients compared to controls (31.5%, 37.2% and 43.2% 
      respectively, all p<0.05). Patients with active (n = 28), but not inactive 
      disease (n = 26) had a higher level of MCP-1 than their respective controls. 
      Levels of eotaxin and MCP-1 correlated with disease duration (r = 0.47 and 
      r = 0.64, both p<0.001) and age in patients, but not with age in controls. At 
      follow-up, MDI was associated with MCP-1(standardized beta = 0.43, p = 0.002) after 
      adjusting for disease duration and gender. High MDI 1 year post-diagnosis 
      predicted high levels of eotaxin and MCP-1 at follow-up (standardized beta = 0.24 
      and 0.29, both p<0.05) after adjusting for disease duration and gender. 
      CONCLUSION: Patients with JDM had higher eotaxin, MCP-1 and IP-10 than controls. 
      High eotaxin and MCP-1 at follow-up was predicted by early disease parameters, 
      and MCP-1 was associated with organ damage at follow-up, highlighting a role of 
      these chemokines in JDM.
FAU - Sanner, Helga
AU  - Sanner H
AD  - Section of Rheumatology, Oslo University Hospital-Rikshospitalet, Oslo, Norway; 
      Norwegian Competence Centre of Pediatric and Adolescent Rheumatology, Oslo 
      University Hospital-Rikshospitalet, Oslo, Norway.
FAU - Schwartz, Thomas
AU  - Schwartz T
AD  - Institute for Experimental Medical Research, Oslo University Hospital-Ulleval, 
      Oslo, Norway; KG Jebsen Cardiac Research Center and Center for Heart Failure 
      Research, University of Oslo, Oslo, Norway; Institute for Clinical Medicine, 
      University of Oslo, Oslo, Norway.
FAU - Flato, Berit
AU  - Flato B
AD  - Section of Rheumatology, Oslo University Hospital-Rikshospitalet, Oslo, Norway; 
      Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Vistnes, Maria
AU  - Vistnes M
AD  - Institute for Experimental Medical Research, Oslo University Hospital-Ulleval, 
      Oslo, Norway; KG Jebsen Cardiac Research Center and Center for Heart Failure 
      Research, University of Oslo, Oslo, Norway.
FAU - Christensen, Geir
AU  - Christensen G
AD  - Institute for Experimental Medical Research, Oslo University Hospital-Ulleval, 
      Oslo, Norway; KG Jebsen Cardiac Research Center and Center for Heart Failure 
      Research, University of Oslo, Oslo, Norway.
FAU - Sjaastad, Ivar
AU  - Sjaastad I
AD  - Institute for Experimental Medical Research, Oslo University Hospital-Ulleval, 
      Oslo, Norway; KG Jebsen Cardiac Research Center and Center for Heart Failure 
      Research, University of Oslo, Oslo, Norway; Department of Cardiology, Oslo 
      University Hospital-Ulleval, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20140319
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (CCL11 protein, human)
RN  - 0 (Chemokine CCL11)
RN  - 0 (Chemokine CCL2)
RN  - Amyopathic dermatomyositis
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Case-Control Studies
MH  - Chemokine CCL11/*blood
MH  - Chemokine CCL2/*blood
MH  - Child
MH  - Child, Preschool
MH  - Dermatomyositis/*blood/diagnosis
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Inflammation/pathology
MH  - Male
MH  - Time Factors
MH  - Young Adult
PMC - PMC3960173
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/03/22 06:00
MHDA- 2015/12/15 06:00
PMCR- 2014/03/19
CRDT- 2014/03/21 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/02/19 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2014/03/19 00:00 [pmc-release]
AID - PONE-D-13-41136 [pii]
AID - 10.1371/journal.pone.0092171 [doi]
PST - epublish
SO  - PLoS One. 2014 Mar 19;9(3):e92171. doi: 10.1371/journal.pone.0092171. eCollection 
      2014.